Ranibizumab

Figure 1 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in WB

Western blot analysis of TP-104CL was performed with Recombinant Human VEGF protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TP-104CL and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.

Figure 2 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in ELISA

ELISA analysis of TP-104CL was performed by coating with Recombinant Human VEGF Protein. Then blocked with BSA, and incubated with Anti-VEGF Therapeutic Antibody (ranibizumab) (TP-104CL). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 3 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in DB

Antigen: Human VEGF protein
Antibody incubation concentration: 2ng/μL.